Trial Profile
A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Hepatitis C vaccine (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2021 Results of meta-analysis assessing agent-based models to perform in-silico simulations of HCV vaccine randomized clinical trials (RCT) under varying assumptions of true vaccine efficacy, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 11 Feb 2021 Primary endpoint (Evaluation of efficacy is chronic HCV infection at 6 months) , has not been met according to results published in the New England Journal of Medicine
- 11 Feb 2021 Results published in the New England Journal of Medicine